WO2021018226A1 - 一种杂环化合物及其应用 - Google Patents
一种杂环化合物及其应用 Download PDFInfo
- Publication number
- WO2021018226A1 WO2021018226A1 PCT/CN2020/105672 CN2020105672W WO2021018226A1 WO 2021018226 A1 WO2021018226 A1 WO 2021018226A1 CN 2020105672 W CN2020105672 W CN 2020105672W WO 2021018226 A1 WO2021018226 A1 WO 2021018226A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- dichloro
- ring
- alkyl
- oxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (12)
- 一种具有式(I)所示结构的杂环化合物:其中:A为-O-或-CH 2-;X为N或C-R 4;Y为N或C-R 5;R 1和R 2独立地选自Br、Cl或C1-C6的烷基;R 4和R 5独立地选自氢、卤素、三氟甲基、氰基、C1-C6的烷基、-OR 6、-NR 6R 7、-CONR 6R 7、C6-C10的芳基或C5-C10的杂芳基;其中,R 6和R 7各自独立地选自氢、C1-C6的烷基、C6-C10的芳基或C5-C10的杂芳基,或者,R 6和R 7与它们相连的原子一起形成3-7元的饱和环基;R 3独立地选自C1-C6的烷基、-NR 8R 9或-CONR 8R 9;或R 3同其所连的碳原子与Y一起形成4-10元的部分饱和的环或4-10元的不饱和环;R 8和R 9独立地选自氢、C1-C6的烷基、羟基取代的C1-C6烷基、C3-C6的环烷基、C6-C10的芳基或C5-C10的杂芳基,且R 8和R 9不同时为氢;或者,R 8和R 9与它们相连的氮原子一起形成4-10元的饱和或不饱和环;Z选自式(Z-1)、式(Z-2)、式(Z-3)、式(Z-4)、式(Z-5)、式(Z-6)、式(Z-7)、式(Z-8)、式(Z-9)、式(Z-10)、式(Z-11)、式(Z-12)、式(Z-13)、或式(Z-14),其中,L选自O、-NR 12-或-(CH 2)-O-;Q选自C或SO;n是0、1、2或3;m是0、1、2或3;R 10和R 11各自独立地选自氢、C1-C6的烷基、C6-C10的芳基或C5-C10的杂芳基,或者R 10和R 11与它们相连的原子一起形成3-6元的饱和或不饱和环;R 12选自氢、C1-C6的烷基、C1-C6的烷基甲酰基、C6-C10的芳基甲酰基或C5-C10的杂芳基甲酰基。
- 权利要求1所述的杂环化合物,其中,所述R 3为C1-C6的烷基、-NR 8R 9或-CONR 8R 9;R 8和R 9独立地选自氢、C1-C6的烷基、羟基取代的C1-C6烷基或C3-C6的环烷基,且R 8和R 9不同时为氢,或者,R 8和R 9与它们相连的氮原子一起形成4-10元的饱和或不饱和环;或者,所述R 3和Y与它们相连的原子一起形成C6-C10的芳环、5-10元的杂芳环、C5-C8的环烷基、吗啉环、哌啶环、N-甲基哌啶环或吡喃环。
- 权利要求1或2所述的杂环化合物,其中,所述R 3为N,N-二甲基甲酰胺基、N,N-二甲基氨基、环丙基氨基、3-羟基氮杂环丁-1-基、氮杂环丁-1-基、3,3-二氟氮杂环丁-1-基、N-甲基-N-异丙基氨基、环戊氨基或N-甲基-N-2-羟基乙基氨基,所述Y为C-H、C-F、C-Cl或C-CH 3。
- 权利要求1或2所述的杂环化合物,其中,所述R 3同其所连的碳原子与Y一起形成苯环、吡咯环、N-甲基吡咯环、环戊烷、环己烷、四氢吡咯环、N-甲基四氢吡咯环、哌啶环或N-甲基哌啶环。
- 权利要求1-4任一项所述的杂环化合物,其中,R 3为-NR 8R 9或-CONR 8R 9;R 8和R 9独立地选自氢、C1-C6的烷基、羟基取代的C1-C6烷基或C3-C6的环烷基,且R 8和R 9不同时为氢;Y为C-F。
- 权利要求1-4任一项所述的杂环化合物,其中,R 3独立地选自-NR 8R 9或-CONR 8R 9;R 8和R 9独立地选自C3-C6的环烷基、C6-C10的芳基或C5-C10的杂芳基;Y为C-H。
- 权利要求1-6任一项所述的杂环化合物,其结构如式(I-1)、式(I-2)、式(I-3)、式(I-4)、式(I-5)、式(I-6)、式(I-7)、式(I-8)、式(I-9)式(I-10)、式(I-11)、式(I-12)、式(I-13)或(I-14)所示,其中,A为-O-或-CH 2-;M为甲基、Cl或F;R 1和R 2独立地选自Br、Cl或C1-C6的烷基;Z选自式(Z-1)、式(Z-2)、式(Z-3)、式(Z-4)、式(Z-5)、式(Z-6)、式(Z-7)、式(Z-8)、式(Z-9)、式(Z-10)、式(Z-11)、式(Z-12)、式(Z-13)、或式(Z-14),其中,L选自O、-NR 12-或-(CH 2)-O-;Q选自C或SO;n是0、1、2或3;m是0、1、2或3;R 10和R 11各自独立地选自氢、C1-C6的烷基、C6-C10的芳基或C5-C10的杂芳基,或者R 10和R 11与它们相连的原子一起形成3-6元的饱和环或3-6元的部分饱和的环;R 12选自氢、C1-C6的烷基、C1-C6的烷基甲酰基、C6-C10的芳基甲酰基或C5-C10的杂芳基甲酰基。
- 药物组合物,其含有权利要求1-8任一项所述的杂环化合物,以及任选的辅料。
- 权利要求1-8任意一项所述的杂环化合物在制备激动甲状腺激素β受体的药物中的用途。
- 一种权利要求1-8任意一项所述的杂环化合物在制备治疗和/或预防由甲状腺激素调节引起的疾病的药物中的用途;优选地,所述由甲状腺激素调节引起的疾病选自代谢疾病(例如肥胖、高脂血症、高胆固醇血症、糖尿病、胰岛素抵抗)、肝脏病变(例如肝脂肪变性、NAFLD(例如,非酒精性脂肪肝炎(NASH)))、心血管疾病(例如动脉粥样硬化、高血压)、甲状腺机能减退或甲状腺癌。
- 一种用于治疗和/或预防由甲状腺激素调节引起的疾病的方法,其包括向有此需要的受试者施用有效量的权利要求1-8任一项所述的杂环化合物的步骤;优选地,所述由甲状腺激素调节引起的疾病选自代谢疾病(例如肥胖、高脂血症、高胆固醇血症、糖尿病、胰岛素抵抗)、肝脏病变(例如肝脂肪变性、NAFLD(例如,非酒精性脂肪肝炎(NASH)))、心血管疾病(例如动脉粥样硬化、高血压)、甲状腺机能减退或甲状腺癌。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910702174.5 | 2019-07-31 | ||
CN201910702174 | 2019-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021018226A1 true WO2021018226A1 (zh) | 2021-02-04 |
Family
ID=74228601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/105672 WO2021018226A1 (zh) | 2019-07-31 | 2020-07-30 | 一种杂环化合物及其应用 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN112300133A (zh) |
TW (1) | TW202115029A (zh) |
WO (1) | WO2021018226A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11091467B2 (en) | 2019-05-08 | 2021-08-17 | Aligos Therapeutics, Inc. | Modulators of THR-β and methods of use thereof |
WO2022242743A1 (zh) * | 2021-05-21 | 2022-11-24 | 深圳微芯生物科技股份有限公司 | 一种杂环化合物及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1933826A (zh) * | 2004-03-22 | 2007-03-21 | 卡罗生物股份公司 | 包含甲状腺受体激动剂的新型药物组合物 |
CN101801960A (zh) * | 2007-09-20 | 2010-08-11 | 霍夫曼-拉罗奇有限公司 | 甲状腺激素类似物的前药 |
WO2019240938A1 (en) * | 2018-06-12 | 2019-12-19 | Fronthera U.S. Pharmaceuticals Llc | Thyroid hormone receptor agonists and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO5160290A1 (es) * | 1999-03-29 | 2002-05-30 | Novartis Ag | Derivados de acido fenoxifeniloxamico sustituido . |
US6790978B2 (en) * | 1999-03-29 | 2004-09-14 | Novartis Ag | Thyromimetic organic compounds |
ATE382602T1 (de) * | 2000-03-31 | 2008-01-15 | Pfizer Prod Inc | Malonsäureamide sowie deren derivate als thyroidrezeptor liganden |
CA2816000A1 (en) * | 2010-11-11 | 2012-05-18 | Redx Pharma Limited | Drug derivatives |
-
2020
- 2020-07-29 TW TW109125661A patent/TW202115029A/zh unknown
- 2020-07-29 CN CN202010743599.3A patent/CN112300133A/zh active Pending
- 2020-07-30 WO PCT/CN2020/105672 patent/WO2021018226A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1933826A (zh) * | 2004-03-22 | 2007-03-21 | 卡罗生物股份公司 | 包含甲状腺受体激动剂的新型药物组合物 |
CN101801960A (zh) * | 2007-09-20 | 2010-08-11 | 霍夫曼-拉罗奇有限公司 | 甲状腺激素类似物的前药 |
WO2019240938A1 (en) * | 2018-06-12 | 2019-12-19 | Fronthera U.S. Pharmaceuticals Llc | Thyroid hormone receptor agonists and uses thereof |
Non-Patent Citations (1)
Title |
---|
HASSAN, A. QUAMRUL ET AL.: "Selective Chemical Rescue of a Thyroid-Hormone-Receptor Mutant, TRβ(H435Y), Identified in Pituitary Carcinoma and Resistance to Thyroid Hormone", ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 47, no. 38, 7 August 2008 (2008-08-07), XP55776688, ISSN: 1433-7851, DOI: 20200915172149X * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11091467B2 (en) | 2019-05-08 | 2021-08-17 | Aligos Therapeutics, Inc. | Modulators of THR-β and methods of use thereof |
WO2022242743A1 (zh) * | 2021-05-21 | 2022-11-24 | 深圳微芯生物科技股份有限公司 | 一种杂环化合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
TW202115029A (zh) | 2021-04-16 |
CN112300133A (zh) | 2021-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2889505C (en) | Gpr40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient | |
WO2020177653A1 (zh) | 吡嗪类衍生物及其在抑制shp2中的应用 | |
US20220162161A1 (en) | Novel compounds and their uses as thyroid hormone receptor agonists | |
JP5008778B2 (ja) | 新規5−フルオロウラシル誘導体 | |
CN111285829B (zh) | 一类PPARγ/δ双重激动剂、其制备方法及其作为药物的用途 | |
EA018894B1 (ru) | N,n-диметил-5-(2-метил-6-((5-метилпиразин-2-ил)карбамоил)бензо-фуран-4-илокси)пиримидин-2-карбоксамид, используемый в качестве активатора глюкокиназы, и содержащая его фармацев-тическая композиция | |
WO2016150255A1 (zh) | 稠环衍生物、其制备方法、中间体、药物组合物及应用 | |
TW201121544A (en) | Novel phenol derivative | |
TWI763147B (zh) | 1,2,4-三嗪-3,5-二酮類化合物及其製備方法和應用 | |
WO2021018226A1 (zh) | 一种杂环化合物及其应用 | |
WO2020228577A1 (zh) | 一种哒嗪酮衍生物及其应用 | |
WO2021175283A1 (zh) | 新型ep4拮抗剂的合成及其在癌症和炎症中的用途 | |
US11261170B2 (en) | Aromatic compound, pharmaceutical composition and use thereof | |
JP6782763B2 (ja) | 新規のピリジニウム化合物 | |
JP5243596B2 (ja) | Hdl−コレステロール上昇剤としての3−トリフルオロメチル−ピラジン−2−カルボン酸アミド誘導体 | |
CN111499591A (zh) | RORγ调节剂 | |
CN113278013B (zh) | 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用 | |
DE102004046623A1 (de) | Neue Pyrimidin-Derivate und ihre Verwendung | |
CN107922375A (zh) | 靶向idh2突变的抗肿瘤化合物及其使用方法 | |
CN107428682B (zh) | 酰胺类衍生物、其制备方法及其在医药上的用途 | |
US20100222394A1 (en) | Method for producing pyrazol-3-yl-benzamide derivative | |
WO2022242743A1 (zh) | 一种杂环化合物及其应用 | |
US20200255417A1 (en) | Novel thiophene compounds, process for synthesis and use thereof | |
TW201404772A (zh) | 噁唑烷酮類衍生物、其製備方法及其在醫藥上的應用 | |
WO2022259993A1 (ja) | PPARα転写活性化剤およびその医薬用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20847250 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20847250 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20847250 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 21.09.2022) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20847250 Country of ref document: EP Kind code of ref document: A1 |